nad+
Cofactors and metabolites · 11 suppliers · $0.08 to $0.26 per mg · 264 registered studies · 86,066 indexed papers
This page holds two records that were compiled separately. The research figures below come from the public registries named under each one, each read on the date printed beside it. The supplier prices at the foot were read on the suppliers own sites on the dates in that table. Nothing here was produced by this publication measuring anything.
Identity and computed properties
PubChem holds this compound as CID 5892, molecular formula C21H27N7O14P2, average mass 663.4 daltons and monoisotopic mass 663.1091 daltons, read on 2026-09-19. Those masses are computed from the deposited structure and were not measured on any material, so they are the expected value an identity check compares against rather than evidence about any vial.
The title that record carries for the CID is Nadide. Its synonym list runs to 198 entries.
Receptors the literature describes
No published paper this search reached describes a receptor this compound acts at.
The registered trial record
An intervention search of clinicaltrials.gov for the term nicotinamide adenine dinucleotide, read on 2026-09-19, returned 264 registered studies: 11 early phase 1, 44 phase 1, 69 phase 2, 26 phase 3, 19 phase 4 and 117 recorded with no phase.
Haukeland University Hospital is lead sponsor on 9 of the 264 records. The remaining 255 name 187 other organizations.
On the date read, the statuses those records carried were 126 completed, 48 recruiting and 37 unknown, among others.
The earliest record the search returns is NCT00051987, first submitted 2003-01-21. That date is a floor, not an origin: earlier work may sit in the registry under a code number this search term does not match.
Registry counts measure registration, not knowledge.
The publication record
PubMed answered 86,066 records for the term nicotinamide adenine dinucleotide on 2026-09-19. Of those, 549 carry a clinical-trial publication type, and 15 of those carry Clinical Trial, Phase III. 6,968 carry the publication type Review, which is other people reading the rest.
PubMed counts measure indexing, so work in venues it does not index is invisible to this figure. The term that produced it is printed above so it can be run again.
Regulatory status
A Drugs@FDA query on 2026-09-19 returned no application record for any of these 9 searches:
- openfda.generic_name:"nadide"
- openfda.substance_name:"nadide"
- openfda.brand_name:"nadide"
- openfda.generic_name:"nicotinamide adenine dinucleotide"
- openfda.substance_name:"nicotinamide adenine dinucleotide"
- openfda.brand_name:"nicotinamide adenine dinucleotide"
- openfda.generic_name:"NAD"
- openfda.substance_name:"NAD"
- openfda.brand_name:"NAD"
Those are results for the 9 searches printed above, and nothing wider. A compound holding an approved application under a name none of those searches covers would not answer any of them, and no dated note of which names were checked, and why those are the ones to check, is recorded here.
Findings, as published reports recorded them
This block was compiled and no finding from a named publication was reached.
Adverse events, as published reports recorded them
This block was compiled and no adverse event from a named publication was reached.
Spontaneous report databases are not used on this page. A count of reports carries no denominator, so it cannot be read as a rate and is not printed as one.
Who it is not given to
No doctor prescribes this. There is no approved product under this name on the Food and Drug Administration record, read 2026-09-19, so there is no label naming who must avoid it and why.
Read this as missing information, not as a clear record. Nobody has published who is at risk, which is not the same as nobody being at risk.
Every row is a price read on that supplier's own site, divided by the milligrams it buys. Cheapest first, which is not a ranking of quality: the columns beside the rate show what this publication could confirm about the evidence behind it. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
Vendor comparison
| Per mg | Price | Supplier | Certificate checkable | Caution on record | What the figure is |
|---|---|---|---|---|---|
| $0.08per mg | $38.39500mg | Panda Peptidesrecord → | not transcribed | not transcribed | discounted from 39.99read 2026-08-23 |
| $0.11per mg | $55.00500mg | GenPeptiderecord → | not transcribed | not transcribed | single vial current price; listed as NAD+ Bufferedread 2026-08-20 |
| $0.11per mg | $110.001000mg | Tex Peptidesrecord → | you can check it | Both retatrutide pages print BPC-157 identifiers verbatim, including the formula, sequence and CAS number, while the vendor's own report reads Retatrutide. The semaglutide and tirzepatide pages are correct. | single vial current priceread 2026-08-24 |
| $0.12per mg | $59.00500mg | Peptirarecord → | not transcribed | not transcribed | single vial current priceread 2026-08-20 |
| $0.13per mg | $65.00500mg | Full Scale Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-25 |
| $0.17per mg | $175.001000mg | Grey Research Peptidesrecord → | not transcribed | not transcribed | single vial current price; listed as NAD+ 1,000mgread 2026-08-25 |
| $0.18per mg | $89.00500mg | Improved Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-26 |
| $0.18per mg | $90.00500mg | Polaris Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-20 |
| $0.19per mg | $189.001000mg | Genesis Peptidesrecord → | not transcribed | not transcribed | single vial current price; tile corroborates at $0.19/mg; 500mg and 750mg options also offered, unpriced in the sentenceread 2026-08-20 |
| $0.20per mg | $199.001000mg | ProPeptidesrecord → | not checkable | The certificate page contains no document, no lot, no figure and no laboratory name. | single vial current price (listed as 1G)read 2026-08-24 |
| $0.26per mg | $130.60500mg | Peptides Warehouserecord → | not transcribed | not transcribed | single vial current price; sentence says it is shown struck through but the was-figure is cut offread 2026-08-20 |
Read between 2026-08-20 and 2026-08-26. Prices move and these were read once.
Sources
Registered study counts, phases, lead sponsors and first-submitted dates: the clinicaltrials.gov public API, one intervention search on the term printed above, read 2026-09-19. Indexed paper counts and publication types: PubMed, the term printed above and that term narrowed by publication type, read 2026-09-19. Formula and computed mass: PubChem, the CID printed above, read 2026-09-19. Application status: the Food and Drug Administration Drugs@FDA database through the agency public endpoint, read 2026-09-19.
The dates in the paragraph above are the dates those fetches ran, stamped in UTC. The dates in the list below are the dates a person read each record. The same record can carry both, a day apart, when a fetch ran after midnight UTC.
- PubChem compound record, CID 5892 read 2026-09-19